225 related articles for article (PubMed ID: 9598779)
21. Mechanism of quinolone resistance in Staphylococcus aureus.
Tanaka M; Wang T; Onodera Y; Uchida Y; Sato K
J Infect Chemother; 2000 Sep; 6(3):131-9. PubMed ID: 11810552
[TBL] [Abstract][Full Text] [Related]
22. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
Schedletzky H; Wiedemann B; Heisig P
J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
[TBL] [Abstract][Full Text] [Related]
23. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase mutations in fluoroquinolone-resistant and methicillin-susceptible and -resistant clinical isolates of Staphylococcus aureus.
Kaatz GW; Seo SM
Antimicrob Agents Chemother; 1998 Jan; 42(1):197-8. PubMed ID: 9449288
[TBL] [Abstract][Full Text] [Related]
25. Rapid method for detection of gyrA and grlA mutations in unrelated strains of Staphylococci susceptible and resistant to levofloxacin.
Messina C; Cafiso V; Campanile F; Santagati M; Stefani S
New Microbiol; 2001 Oct; 24(4):347-53. PubMed ID: 11718372
[TBL] [Abstract][Full Text] [Related]
26. Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro.
Gootz TD; Zaniewski R; Haskell S; Schmieder B; Tankovic J; Girard D; Courvalin P; Polzer RJ
Antimicrob Agents Chemother; 1996 Dec; 40(12):2691-7. PubMed ID: 9124824
[TBL] [Abstract][Full Text] [Related]
27. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
Coskun-Ari FF; Bosgelmez-Tinaz G
Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
[TBL] [Abstract][Full Text] [Related]
28. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
29. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
Linde HJ; Schmidt M; Fuchs E; Reischl U; Niller HH; Lehn N
Antimicrob Agents Chemother; 2001 May; 45(5):1553-7. PubMed ID: 11302827
[TBL] [Abstract][Full Text] [Related]
30. Molecular epidemiology and mutations at gyrA and parC genes of ciprofloxacin-resistant Escherichia coli isolates from a Taiwan medical center.
Chen JY; Siu LK; Chen YH; Lu PL; Ho M; Peng CF
Microb Drug Resist; 2001; 7(1):47-53. PubMed ID: 11310803
[TBL] [Abstract][Full Text] [Related]
31. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra.
Kocagöz T; Hackbarth CJ; Unsal I; Rosenberg EY; Nikaido H; Chambers HF
Antimicrob Agents Chemother; 1996 Aug; 40(8):1768-74. PubMed ID: 8843279
[TBL] [Abstract][Full Text] [Related]
32. Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.
Lawrence LE; Frosco M; Ryan B; Chaniewski S; Yang H; Hooper DC; Barrett JF
Antimicrob Agents Chemother; 2002 Jan; 46(1):191-5. PubMed ID: 11751133
[TBL] [Abstract][Full Text] [Related]
33. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus.
Fukuda H; Hori S; Hiramatsu K
Antimicrob Agents Chemother; 1998 Aug; 42(8):1917-22. PubMed ID: 9687384
[TBL] [Abstract][Full Text] [Related]
34. Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Presterl E; Mueller-Uri P; Grisold A; Georgopoulos A; Graninger W
Eur J Clin Microbiol Infect Dis; 2001 Jul; 20(7):486-9. PubMed ID: 11561805
[TBL] [Abstract][Full Text] [Related]
35. Detection of grlA and gyrA mutations in 344 Staphylococcus aureus strains.
Wang T; Tanaka M; Sato K
Antimicrob Agents Chemother; 1998 Feb; 42(2):236-40. PubMed ID: 9527766
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus.
Fitzgibbon JE; John JF; Delucia JL; Dubin DT
Antimicrob Agents Chemother; 1998 Aug; 42(8):2122-4. PubMed ID: 9687420
[TBL] [Abstract][Full Text] [Related]
37. Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-resistant and -susceptible Staphylococcus aureus strains.
Jones ME; Visser MR; Klootwijk M; Heisig P; Verhoef J; Schmitz FJ
Antimicrob Agents Chemother; 1999 Feb; 43(2):421-3. PubMed ID: 9925551
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of a high-density oligonucleotide array for characterization of grlA, grlB, gyrA and gyrB mutations in fluoroquinolone resistant Staphylococcus aureus isolates.
Couzinet S; Yugueros J; Barras C; Visomblin N; Francois P; Lacroix B; Vernet G; Lew D; Troesch A; Schrenzel J; Jay C
J Microbiol Methods; 2005 Feb; 60(2):275-9. PubMed ID: 15590102
[TBL] [Abstract][Full Text] [Related]
39. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
Akasaka T; Tanaka M; Yamaguchi A; Sato K
Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
[TBL] [Abstract][Full Text] [Related]
40. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.
Ferrero L; Cameron B; Crouzet J
Antimicrob Agents Chemother; 1995 Jul; 39(7):1554-8. PubMed ID: 7492103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
